Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2312
Peer-review started: October 15, 2020
First decision: December 28, 2020
Revised: January 4, 2021
Accepted: February 19, 2021
Article in press: February 19, 2021
Published online: April 6, 2021
Processing time: 165 Days and 14.8 Hours
Mandibular advancement devices (MADs) are used to treat mild to moderate obstructive sleep apnea (OSA), but there is a risk that the underlying condition can worsen in the long-term. Therefore, this case report is based on biomimetic oral appliance therapy as an alternative to MADs, which was found to be beneficial in the treatment of a case with severe OSA.
An overnight sleep study was undertaken in a 50-year-old male with excessive daytime sleepiness that lead to a diagnosis of severe OSA as the apnea-hypopnea index (AHI) was found to be 32.8/h. Since the patient was unable to comply with continuous positive airway pressure therapy and declined surgical intervention, treatment with a MAD was initiated. Approximately 10 years later, another sleep study was performed with no MAD in the mouth, which revealed an AHI of 67.9/h. In view of the deterioration in sleep quality, the patient sought alternative treatment and elected on biomimetic oral appliance therapy, using a mandibular repositioning nighttime appliance (mRNA appliance®, Vivos Therapeutics, Inc., United States). After 10 mo, another sleep study was performed with no device in the patient’s mouth, which revealed an AHI of 11.8/h, a mean oxygen saturation of 94% and a mean oxygen desaturation index of 5.3% while sleeping. Finite-element analysis of the pre- and post-treatment study models of the upper jaw showed localized size increases of 15%-17% in the premolar regions and 15%-23% in the molar regions.
In adults with severe OSA that are unable to accept continuous positive airway pressure or surgical treatment, biomimetic oral appliance therapy may be preferable over MADs since biomimetic oral appliance therapy may be able to prevent worsening of sleep parameters by remodeling the nasomaxillary complex. Long-term follow up studies are required to verify these novel findings.
Core Tip: Mandibular advancement devices (MADs) are considered to be a first line therapy in adult cases of mild to moderate obstructive sleep apnea that are unable to comply with continuous positive airway pressure. However, both MADs and continuous positive airway pressure represent a lifetime of therapy and there is a risk that the underlying condition may worsen over time as the patient undergoes ageing. In contrast, biomimetic oral appliance therapy differs from MADs since it attempts to mimic normal craniofacial growth and development. The primary target of biomimetic oral appliance therapy is the nasomaxillary complex, which is non-surgically corrected even in adult cases followed by re-coordination with the mandible.